CVRx, Inc. Common Stock (CVRX) Stock
Key stats
- Market cap
- $19.95M
- Price / Earnings ratio
- -0.4x
- EPS (TTM)
- -$2.00
- Volume
- Loading
- 52-week high
- $10.28
- 52-week low
- $0.67
Source: third-party data provider, as of November 13, 2026
Compare with CVRX
Recent news

CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRX

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
CVRX

CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
CVRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 22.37
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.26
- MACD histogram
- -0.03
- SMA 50
- $1.95
- Price below SMA 50
- EMA 50
- $1.93
- Price below EMA 50
- SMA 200
- $5.07
- Price below SMA 200
- EMA 200
- $4.73
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRX

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
CVRX

CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
CVRX

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
CVRX

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRX

CVRx Q2 Earnings Call Highlights
CVRx Q2 Earnings Call Highlights
CVRX

Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics
CVRX

CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?
CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?
CVRX

CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About CVRx, Inc. Common Stock
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Brent Binkowski | Chief Operating Officer | 1969 |
| Dr. Philip B. Adamson M.D., M.Sc. | Chief Medical Officer | 1961 |
| Mr. Matt Klein | Vice President, Legal & Compliance Officer | — |
| Mr. Paul Verrastro | Interim Head of Sales | 1963 |
| Mr. Patrick Lyon | Vice President of Marketing | — |
| Mr. Gregory Morrison | Chief Human Resources Officer | 1964 |
| Mr. Jared Oasheim | Consultant | 1983 |
| Ms. Bonnie Handke M.B.A., R.N. | Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 22.37
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.26
- MACD histogram
- -0.03
- SMA 50
- $1.95
- Price below SMA 50
- EMA 50
- $1.93
- Price below EMA 50
- SMA 200
- $5.07
- Price below SMA 200
- EMA 200
- $4.73
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $1.50
- Average
- $2.83
- High
- $5.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +13.0 | -17.5 | -30.0 | -5.3 | -5.8 | -46.2 | -42.4 | -7.8 | -48.9 |



